Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biotronik commences Orsiro coronary stent trial

Biotronik commences Orsiro coronary stent trial

14th July 2011

Biotronik has announced the commencement of its new clinical trial evaluating the efficacy of its Orsiro sirolimus-eluting coronary stent.

European patients have now begun to receive treatment as part of the Bioflow-II study, which is comparing Orsiro to Abbott's Xience Prime everolimus-eluting stent for the treatment of heart conditions.

The primary endpoint of the study will be in-stent late lumen loss at nine months, while secondary performance metrics is lesion revascularisation, vessel revascularisation and lesion failure.

It is a follow-up to the Bioflow-I study, the initial clinical trial of the stent, which was able to meet its primary efficacy endpoint.

Alain Aimonetti, vice-president for sales and marketing at Biotronik's vascular intervention division, said: "The exciting addition of the Orsiro hybrid drug-eluting stent allows us to offer the world's most advanced product portfolio for vascular intervention."

Last month, the firm launched its new Lumax 540 VR-T DX, an innovative single-chamber implantable cardiac defibrillator.ADNFCR-8000103-ID-800621987-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.